Antioxidant power measurement in platelet concentrates treated by two pathogen inactivation systems in different blood centres. Issue 1 (14th August 2020)

• Record Type: Journal Article
• Authors: Lotens, Anaïs; Abonnenc, Mélanie; Malvaux, Nicolas; Schuhmacher, Anne; Prudent, Michel; Rapaille, André
• Is Part Of: Vox sanguinis. Volume 116:Issue 1(2021)
• Page Start: 53
• Page End: 59
• Publication Date: 2020-08-14
• Subjects: antioxidant power -- platelet concentrates -- pathogen inactivation; Blood -- Periodicals; Blood -- Transfusion -- Periodicals; Immunohematology -- Periodicals; Immunopathology -- Periodicals; 615.39
• DOI: 10.1111/vox.12979
• Languages: English
• ISSNs: 0042-9007

Abstract

Abstract : Background and objectives: The antioxidant power measurement can be useful to validate the execution of the pathogen inactivation treatment of platelet concentrates. The aim of this study is to evaluate the technology on different blood preparations including INTERCEPT and Mirasol treatments that are in routine use in Belgium and Luxemburg. Materials and methods: The antioxidant power measurement was tested on 78 apheresis platelet concentrates and 54 pools of buffy‐coats‐derived platelet concentrates before and after INTERCEPT treatment. In addition, 100 Reveos platelet pools were tested before and after Mirasol treatment. The antioxidant power was quantified electrochemically using disposable devices and was expressed as equivalent ascorbic acid concentration. Results: Mean results for apheresis platelet concentrates were of 90 ± 14 and 35 ± 10 µmol/l eq. ascorbic acid before and after INTERCEPT treatment, respectively. The mean results for pools of buffy‐coats‐derived platelet concentrates were of 81 ± 10 and 29 ± 4 eq. µmol/l ascorbic acid before and after INTERCEPT treatment, respectively. For buffy‐coats‐derived platelet concentrates treated by Mirasol technology, the mean results were of 98 ± 11 and 32 ± 10 µmol/l eq. ascorbic acid before and after illumination, respectively. Conclusion: The antioxidant power significantly decreases with pathogen inactivation treatments for platelet concentrates treated by INTERCEPT or Mirasol technologies.